[1]郑爱青,于金明.对乏氧和射线应答的嵌合性基因启动子的研究进展[J].国际放射医学核医学杂志,2004,28(2):74-77.
　ZHENG Ai-qing,YU Jin-ming.Development of chimeric gene promoters responsive to hypoxia and ionizing radiation[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(2):74-77.
点击复制

对乏氧和射线应答的嵌合性基因启动子的研究进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
28
期数:
2004年第2期
页码:
74-77
栏目:
核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Development of chimeric gene promoters responsive to hypoxia and ionizing radiation
作者:
郑爱青;  于金明
250117 济南, 山东省肿瘤医院基础研究中心
Author(s):
ZHENG Ai-qing;  YU Jin-ming
Basic Research Center, Shan dong Tumor Hospital, Jinan 250117, China
关键词:
放射治疗; 基因治疗; 肿瘤
Keywords:
radiotherapy; gene therapy; tumor
分类号:
Q691;R730.55
摘要:
介绍两种应用射线和乏氧应答启动子调节的GDEPT(定向基因酶前体药物治疗)系统。用治疗性、条件性或肿瘤特异性启动子控制GDEPT是一种控制靶基因在肿瘤内表达的方法。通过选择性启动子,使基因靶向肿瘤内表达,提高特异性和靶向性,解决了肿瘤基因治疗中的主要限制。
Abstract:
We describe two systems that make use of gene, directed enzyme prodrug therapy, regulated by radiation or hypoxic, responsive promoters. The use of treatment-, condition- or tumor-specific promoters to control gene-directed enzyme prodrug therapy is one such method for targeting gene expression to the tumor. The development of such strategies that achieve tumor targeted expression of genes via selective promoters will enable improved specificity and targeting thereby addressing one of the major limitations of cancer gene therapy.

参考文献/References:

[1] Marples B, Scott SD, Hendry JH, et al. Development of synthetic promoters for radiation-mediated gene therapy[J].Gene Ther, 2000, 7(6):511-517.
[2] Scott SD, Marples B. Comment on the use of the cre/loxP recombinase system for gene therapy vectors[J]. Gene Ther, 2000, 7(19):1706.
[3] Kaspar BK, Vissel B, Bengoechea T, et al. Adeno-associated virus effectively mediates conditional gene modification in the brain[J]. Proc Natl Acad Sci USA, 2002, 9(4):2320-2325.
[4] Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases[J]. Cancer Res, 1999, 59(22):5830-5835.
[5] Greco O, Marples B, Dachs GU, et al. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation[J].Gene Ther, 2002, 9(20):1403-1411.
[6] Fillat C, Carrio M, Cascante A, et al. Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene/ganciclovir system:fifteen years of application[J].Curr Gene Ther, 2003, 3(1):13-26.
[7] Springer C J, Niculescu-Duvaz I. Prodrug-activating systems in suicide gene therapy[J]. J Clin Invest, 2000, 105(9):1161-1167.
[8] Patterson AV, Saunders MP, Greco O. Prodrugs in genetic chemoradiotherapy[J]. Curr Pharm Des, 2003, 9(26):2131-2154.
[9] Dilber MS, Phelan A, Aints A, et al. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22[J]. Gene Ther, 1999, 6(1):12-21.
[10] Rogulski KR, Wing MS, Paielli DL, et al. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytoxicity and radiosensitization[J]. Hum Gene Ther, 2000, 11(1):67-76.
[11] Cunningham S, Boyd M, Brown MM, et al. A gene therapy approach to enhance the targeted radiotherapy of neuroblastoma[J]. Med Pediatr Oncol, 2000, 35(6):708-711.
[12] Epperly MW, Gretton JA, DeFillippi SJ, et al. Modulation of radiation-induced cytokine elevation associated with esophagitis and esophageal stricture by manganese superoxide dismutase-plasmid/liposome(SOD2-PL) gene therapy[J]. Radiat Res, 2001, 155(1):2-14.

相似文献/References:

[1]章文成,杨占山.VEGF的放射生物学特性及其应用[J].国际放射医学核医学杂志,2005,29(1):33.
　ZHANG Wen-cheng,YANG Zhan-shan.The radiation-biological characteristics and application of vascular endothelial growth factor[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(2):33.
[2]姜炜.血管的辐射损伤[J].国际放射医学核医学杂志,2005,29(1):37.
　JIANG Wei.Radiation injury of blood vessels[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(2):37.
[3]袁志斌.89Sr及联合治疗转移性骨肿瘤的临床应用[J].国际放射医学核医学杂志,2005,29(2):53.
　YUAN Zhi-bin.The clinical application of strontium-89 concomitant use with other modalities in the treatment of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(2):53.
[4]余永利.不摄取131I的甲状腺癌治疗[J].国际放射医学核医学杂志,2005,29(2):57.
　YU Yong-li.Treatment of non-uptaking 131I thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(2):57.
[5]陈立波,朱瑞森.NIS在肿瘤核素基因显像与治疗中的应用研究[J].国际放射医学核医学杂志,2005,29(2):70.
　CHEN Li-bo,ZHU Rui-sen.Progress of application study on sodium/iodide symporter as a radionuclide imaging and therapeutic gene[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(2):70.
[6]赵伟,张秀丽.PET报告基因显像研究进展[J].国际放射医学核医学杂志,2005,29(5):238.
　ZHAO Wei,ZHANG Xiu-li.The progress of PET based reporter gene imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(2):238.
[7]盛晓芳,管一晖,赵军,等.PET-CT在脑胶质瘤放射治疗靶区确定中的应用[J].国际放射医学核医学杂志,2005,29(6):241.
　SHENG Xiao-fang,GUAN Yi-hui,ZHAO Jun,et al.Application of PET-CT in delineation of radiotherapy planning target volume for glioma[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(2):241.
[8]张永权,巴特尔,刘文力.多发性脑转移瘤的立体定向伽玛刀治疗[J].国际放射医学核医学杂志,2004,28(2):94.
　Zhang Yong-quan,Bateer,Liu Wen-li.The treatment on multiple brain metastasis by stereotactic gamma knife[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(2):94.
[9]王佳琼,王自正.基因转移技术与基因靶向性核素治疗[J].国际放射医学核医学杂志,2004,28(4):145.
　WANG Jia-qiong,WANG Zi-zheng.Gene transfer technology and genetic radioisotope targeting therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(2):145.
[10]陈再君,蒋宁一.131I治疗甲亢后致甲减的研究变迁[J].国际放射医学核医学杂志,2004,28(4):153.
　CHEN Zai-jun,JIANG Ning-yi.The research vicissitudes of hypothyroidism after 131I therapy for hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(2):153.

备注/Memo

备注/Memo:
收稿日期:2003-12-11。
基金项目:山东省重大攻关项目(031050102)
更新日期/Last Update: 1900-01-01